Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW274150 · 5 trials · 4 indications
Power Doppler ultrasonographic measurement of synovial vascularity
| Arm | Type | Description |
|---|---|---|
| GW274150 60 mg once daily for 28 days | EXPERIMENTAL | 60 mg GW274150 taken once daily for 28 days |
| Prednisolone 7.5 mg once daily for 28 days | ACTIVE_COMPARATOR | 7.5 mg prednisolone taken once daily for 28 days |
| Placebo once daily for 28 days | PLACEBO_COMPARATOR | Placebo taken once daily for 28 days |
| Arm 1 | EXPERIMENTAL | GW274150 - 5mg or 30mg |
| Arm 2 | PLACEBO_COMPARATOR | Placebo to match GW274150 |
| Sequence 1 | EXPERIMENTAL | Subjects will receive Placebo in period 1, Singulair 10 milligrams (mg) in period 2 and GW274150 90 mg in period 3. |
| Sequence 2 | EXPERIMENTAL | Subjects will receive Placebo in period 1, GW274150 90 mg in period 2 and Singulair 10 mg in period 3. |
| Sequence 3 | EXPERIMENTAL | Subjects will receive Singulair 10 mg in period 1, Placebo in period 2 and GW274150 90 mg in period 3. |
| Sequence 4 | EXPERIMENTAL | Subjects will receive Singulair 10 mg in period 1, GW274150 90 mg in period 2 and Placebo in period 3. |
| Sequence 5 | EXPERIMENTAL | Subjects will receive GW274150 90 mg in period 1, Placebo in period 2 and Singulair 10 mg in period 3. |
| Sequence 6 | EXPERIMENTAL | Subjects will receive GW274150 90 mg in period 1, Singulair 10 mg in period 2 and Placebo in period 3. |
| Name | Type | Description |
|---|---|---|
| GW274150 | DRUG | 60 mg /day |
| Prednisolone | DRUG | 7.5 mg/day |
| Placebo | OTHER | Placebo |
| Singulair | DRUG | Singulair will be available as over encapsulated 10 mg orange tablets. |
Inclusion criteria: * Diagnosis of rheumatoid arthritis according to the revised 1987 criteria of the American College of Rheumatology * Female subjects who are not capable of becoming pregnant * Active disease defined as Disease Activity Score (DAS) 28 = 4.0 and at least one metacarpal-phalangeal ...
GW274150 is an investigational small molecule being studied for the prophylactic treatment of migraine, the treatment of acute migraine, mild asthma, and rheumatoid arthritis. It is being developed by GSK plc (GSK). The drug is currently in Phase 2 clinical development for migraine and rheumatoid arthritis.
GW274150 is a small molecule that targets inducible nitric oxide synthase (iNOS). By inhibiting this enzyme, it may reduce the production of nitric oxide, which is thought to play a role in inflammation and pain pathways relevant to migraine, asthma, and rheumatoid arthritis.
GW274150 is being developed by GSK plc, a global biopharmaceutical company listed on the New York Stock Exchange under the ticker GSK. GSK has sponsored multiple clinical trials of GW274150 across different indications.
GW274150 is in Phase 2 clinical development. It has completed Phase 2 trials for the prophylactic treatment of migraine and for acute migraine, as well as a Phase 2 trial in rheumatoid arthritis. A Phase 1 trial in mild asthma has also been completed.
GW274150 has been studied in four completed clinical trials. These include NCT00242866 for migraine prophylaxis, NCT00319137 for acute migraine, NCT00273013 for mild asthma, and NCT00370435 for rheumatoid arthritis. All trials have been completed, with no active trials currently ongoing.
GW274150 is a distinct investigational compound developed by GSK. It is not known to be the same as any other marketed migraine medication. Its mechanism of action, targeting inducible nitric oxide synthase, differs from common migraine treatments such as triptans or gepants.